Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone716-849-6810
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.14 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/26/2019 (Estimated)
OptionableNot Optionable
Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions
What is Cleveland BioLabs' stock symbol?
Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."
How were Cleveland BioLabs' earnings last quarter?
Cleveland BioLabs, Inc. (NASDAQ:CBLI) issued its quarterly earnings data on Wednesday, November, 14th. The biotechnology company reported ($0.10) EPS for the quarter. The biotechnology company earned $0.28 million during the quarter. Cleveland BioLabs had a negative net margin of 314.68% and a negative return on equity of 76.12%. View Cleveland BioLabs' Earnings History.
When is Cleveland BioLabs' next earnings date?
Has Cleveland BioLabs been receiving favorable news coverage?
Press coverage about CBLI stock has been trending neutral this week, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cleveland BioLabs earned a news impact score of 0.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the near term.
Who are some of Cleveland BioLabs' key competitors?
Some companies that are related to Cleveland BioLabs include Senomyx (SNMX), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Vitality Biopharma (VBIO), Bioanalytical Systems (BASI), US Stem Cell (USRM), Geovax Labs (GOVX), Protalex (PRTX), Tenax Therapeutics (TENX), ALGAE TEC LTD/S (ALGXY), National Research (NRCIB), National Research (NRCIA), Redpoint Bio (RPBC) and VIRALYTICS Ltd/S (VRACY).
What other stocks do shareholders of Cleveland BioLabs own?
Who are Cleveland BioLabs' key executives?
Cleveland BioLabs' management team includes the folowing people:
- Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, CEO & Interim Principal Financial Officer (Age 46)
- Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 65)
- Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 63)
- Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
- Dr. Andrei Purmal Ph.D., VP of Chemistry
How do I buy shares of Cleveland BioLabs?
Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cleveland BioLabs' stock price today?
One share of CBLI stock can currently be purchased for approximately $1.62.
How big of a company is Cleveland BioLabs?
Cleveland BioLabs has a market capitalization of $18.31 million and generates $1.14 million in revenue each year.
What is Cleveland BioLabs' official website?
How can I contact Cleveland BioLabs?
Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]
MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
